+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologic Medications for Psoriasis Market - Global Forecast 2026-2032- Product Image
Biologic Medications for Psoriasis Market - Global Forecast 2026-2032- Product Image
Sale

Biologic Medications for Psoriasis Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6079387
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologic Medications for Psoriasis Market is projected to reach USD 27.19 Billion in 2026. It is expected to continue growing at a CAGR of 10.00%, reaching USD 48.12 Billion by 2032.

Biologic Medications for Psoriasis: Executive Overview

Biologic medications have reshaped psoriasis care by targeting specific immune pathways associated with disease activity. Their clinical role is strongest in moderate-to-severe disease, psoriatic arthritis, and cases where conventional systemic treatment or phototherapy is insufficient. Treatment selection increasingly considers efficacy, safety, comorbidities, administration preferences, treatment persistence, and access conditions rather than lesion clearance alone.

How Psoriasis Care Is Being Transformed

The treatment landscape is shifting toward earlier recognition of candidates for advanced therapy, more individualized treatment sequencing, and broader use of objective disease-assessment tools. Long-term management is also influenced by adherence, dose convenience, immunogenicity, safety monitoring, and the management of comorbid conditions such as psoriatic arthritis, cardiovascular risk, obesity, and inflammatory bowel disease. Biosimilar availability and evolving reimbursement policies are further changing procurement and prescribing decisions.

Artificial Intelligence and the Next Layer of Clinical Intelligence

Artificial intelligence can support psoriasis diagnosis, severity assessment, image interpretation, treatment-response tracking, and identification of patients at risk of nonadherence. Its practical value depends on representative clinical data, transparent validation, privacy safeguards, and integration into clinician workflows. AI should complement-not replace-clinical judgment, particularly where skin-tone diversity, overlapping dermatoses, comorbidities, or incomplete patient histories may affect model reliability.

Regional Insights Across Psoriasis Biologic Adoption

North America generally combines specialist capacity, established biologic pathways, and broad use of advanced therapies, while affordability and payer authorization remain important constraints. Europe benefits from mature dermatology networks and health-technology assessment, with access varying across national systems. Asia-Pacific shows substantial clinical and policy diversity, with Japan, South Korea, Australia, China, and India differing in reimbursement, regulatory pathways, and specialist availability. Latin America is shaped by uneven public coverage, private-sector access, and biosimilar development. Middle Eastern access is concentrated in better-resourced systems, while Africa faces wider limitations in diagnosis, specialist care, procurement, and continuity of treatment.

Group-Level Differences Across ASEAN, BRICS, the EU, G7, GCC, and NATO

ASEAN markets reflect varied regulatory maturity, healthcare financing, and specialist distribution, making regional harmonization and practical treatment guidelines valuable. BRICS members span highly different public and private healthcare structures, with local manufacturing, procurement policy, and affordability influencing access. The European Union emphasizes comparative clinical value, national reimbursement decisions, and coordinated regulatory standards. G7 systems generally have advanced specialist infrastructure but continue to manage budget impact and access criteria. GCC countries often possess strong tertiary-care capacity alongside reliance on centralized procurement and imported therapies. NATO membership is not a healthcare market category, yet its countries encompass diverse national systems; the relevant implications are resilience of supply, regulatory alignment, and continuity of essential medicines.

Country Perspectives on Biologic Psoriasis Treatment

Australia and Canada combine specialist-led care with public reimbursement rules that shape eligibility and treatment sequencing. Brazil and Mexico show strong private-sector activity but uneven public access across regions. China and India are marked by large patient populations, expanding specialist capacity, and meaningful differences between urban and rural care. Japan and South Korea have sophisticated healthcare systems with distinct regulatory and reimbursement requirements. France, Germany, Italy, Spain, and the United Kingdom rely on structured clinical guidance and public or statutory coverage, while national formularies and local access pathways differ. The United States offers broad specialist availability and multiple treatment options, but insurance authorization, affordability, and continuity of coverage remain central considerations. Russia’s access environment is influenced by public procurement, economic conditions, and availability through regional healthcare systems.

Priorities for Leaders in Psoriasis Biologic Care

Industry leaders should align clinical evidence with outcomes that matter to patients, including durable skin clearance, symptom relief, joint protection, quality of life, and treatment convenience. They should strengthen evidence across diverse skin tones and comorbidity profiles, support responsible biosimilar adoption, and design access programs that reflect public and private reimbursement structures. Digital tools should be clinically validated and interoperable with care workflows. Supply-chain resilience, transparent pharmacovigilance, patient education, and partnerships with dermatology and rheumatology providers are essential to improving appropriate and sustained use.

Research Methodology for the Executive Summary

This summary uses a structured qualitative synthesis of established clinical, regulatory, reimbursement, and healthcare-delivery themes relevant to biologic medications for psoriasis. The analysis compares treatment needs across the specified regions, groups, and countries while avoiding unsupported numerical claims. Interpretation is organized around clinical practice, access, policy, technology, and operational factors. Because healthcare systems and guidance evolve, market-specific conclusions should be validated against current national clinical guidelines, regulatory documents, reimbursement policies, and peer-reviewed evidence before implementation.

Conclusion: Advancing Effective and Equitable Psoriasis Care

Biologic medications remain central to modern management of moderate-to-severe psoriasis, but their impact depends on more than therapeutic innovation. Effective care requires accurate diagnosis, appropriate patient selection, sustained adherence, coordinated management of comorbidities, and dependable access. Regional and country differences make adaptable evidence, responsible pricing and procurement, validated digital support, and resilient delivery systems essential to improving outcomes across diverse healthcare environments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biologic Medications for Psoriasis Market, by Drug Class
7.1. Introduction
7.2. Interleukin 12/23 Inhibitors
7.3. Interleukin 17 Inhibitors
7.3.1. Brodalumab
7.3.2. Ixekizumab
7.3.3. Secukinumab
7.4. Interleukin 23 Inhibitors
7.4.1. Guselkumab
7.4.2. Risankizumab
7.4.3. Tildrakizumab
7.5. Tumor Necrosis Factor Alpha Inhibitors
7.5.1. Adalimumab
7.5.2. Etanercept
7.5.3. Infliximab
8. Biologic Medications for Psoriasis Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous Infusion
8.3. Subcutaneous Injection
9. Biologic Medications for Psoriasis Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Specialty Pharmacies
10. Biologic Medications for Psoriasis Market, by Patient Age Group
10.1. Introduction
10.2. Adult Patients
10.3. Pediatric Patients
11. Biologic Medications for Psoriasis Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Biologic Medications for Psoriasis Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Biologic Medications for Psoriasis Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc
15.2. Amgen Inc
15.3. AstraZeneca plc
15.4. Biogen Inc
15.5. Boehringer Ingelheim International GmbH
15.6. Bristol-Myers Squibb Company
15.7. Celgene Corporation
15.8. Celltrion Inc
15.9. Eli Lilly and Company
15.10. Johnson & Johnson Services Inc
15.11. Merck & Co Inc
15.12. Novartis AG
15.13. Pfizer Inc
15.14. Samsung Bioepis Co Ltd
15.15. UCB S.A.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Biologic Medications for Psoriasis Market, Years Considered for the Study
FIGURE 2. Global Biologic Medications for Psoriasis Market, Research Design
FIGURE 3. Global Biologic Medications for Psoriasis Market, Research Framework
FIGURE 4. Global Biologic Medications for Psoriasis Market, Data Triangulation
FIGURE 5. Global Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Biologic Medications for Psoriasis Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Biologic Medications for Psoriasis Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Biologic Medications for Psoriasis Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Biologic Medications for Psoriasis Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Biologic Medications for Psoriasis Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Biologic Medications for Psoriasis Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Biologic Medications for Psoriasis Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Biologic Medications for Psoriasis Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Biologic Medications for Psoriasis Market Segmentation & Coverage
TABLE 2. Global Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 3. Global Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Interleukin 12/23 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Interleukin 12/23 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Interleukin 12/23 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Interleukin 17 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Interleukin 17 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Interleukin 17 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Brodalumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Brodalumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Brodalumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ixekizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ixekizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ixekizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Secukinumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Secukinumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Secukinumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Interleukin 23 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Interleukin 23 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Interleukin 23 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Guselkumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Guselkumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Guselkumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Risankizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Risankizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Risankizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Tildrakizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Tildrakizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Tildrakizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Tumor Necrosis Factor Alpha Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Tumor Necrosis Factor Alpha Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Tumor Necrosis Factor Alpha Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Adalimumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Adalimumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Adalimumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Etanercept Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Etanercept Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Etanercept Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Infliximab Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Infliximab Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Infliximab Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 44. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 61. Global Adult Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Adult Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Adult Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Pediatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Pediatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Pediatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. North America Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. North America Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 78. North America Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 79. North America Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 80. North America Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 81. North America Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 82. North America Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. North America Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 84. Latin America Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Latin America Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 86. Latin America Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 87. Latin America Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 88. Latin America Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 89. Latin America Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. Latin America Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Latin America Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. Europe Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Europe Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 94. Europe Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 95. Europe Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 96. Europe Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 97. Europe Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. Europe Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Europe Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 100. Middle East Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Middle East Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 102. Middle East Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 103. Middle East Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 104. Middle East Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 105. Middle East Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. Middle East Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. Middle East Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 108. Africa Biologic Medications for Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Africa Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. Africa Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 111. Africa Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 112. Africa Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 113. Africa Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. Africa Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. Africa Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. Global Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. ASEAN Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. ASEAN Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 119. ASEAN Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 120. ASEAN Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 121. ASEAN Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 122. ASEAN Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 123. ASEAN Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. ASEAN Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. GCC Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. GCC Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 127. GCC Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 128. GCC Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 129. GCC Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 130. GCC Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. GCC Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. GCC Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. European Union Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. European Union Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 135. European Union Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 136. European Union Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 137. European Union Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 138. European Union Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. European Union Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. European Union Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 141. BRICS Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. BRICS Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 143. BRICS Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 144. BRICS Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 145. BRICS Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 146. BRICS Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 147. BRICS Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. BRICS Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 149. G7 Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. G7 Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 151. G7 Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 152. G7 Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 153. G7 Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 154. G7 Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. G7 Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. G7 Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. NATO Biologic Medications for Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. NATO Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 159. NATO Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 160. NATO Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 161. NATO Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 162. NATO Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. NATO Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. NATO Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 165. Global Biologic Medications for Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. United States Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 167. United States Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 168. United States Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 169. United States Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 170. United States Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 171. United States Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 172. United States Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. United States Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. Canada Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 175. Canada Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 176. Canada Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 177. Canada Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 178. Canada Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 179. Canada Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. Canada Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Canada Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Mexico Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 183. Mexico Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 184. Mexico Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 185. Mexico Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 186. Mexico Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 187. Mexico Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. Mexico Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. Mexico Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. Brazil Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 191. Brazil Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 192. Brazil Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 193. Brazil Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 194. Brazil Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 195. Brazil Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 196. Brazil Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Brazil Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. United Kingdom Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 199. United Kingdom Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 200. United Kingdom Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 201. United Kingdom Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 202. United Kingdom Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 203. United Kingdom Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 204. United Kingdom Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. United Kingdom Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 206. Germany Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 207. Germany Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. Germany Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 209. Germany Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 210. Germany Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 211. Germany Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. Germany Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. Germany Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 214. France Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 215. France Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 216. France Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 217. France Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 218. France Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 219. France Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. France Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. France Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Russia Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 223. Russia Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 224. Russia Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 225. Russia Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 226. Russia Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 227. Russia Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 228. Russia Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Russia Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 230. Italy Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 231. Italy Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 232. Italy Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 233. Italy Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 234. Italy Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 235. Italy Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 236. Italy Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Italy Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. Spain Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 239. Spain Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 240. Spain Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 241. Spain Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 242. Spain Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 243. Spain Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. Spain Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. Spain Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. China Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 247. China Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 248. China Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 249. China Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 250. China Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 251. China Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. China Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 253. China Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 254. India Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 255. India Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 256. India Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 257. India Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 258. India Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 259. India Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 260. India Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. India Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Japan Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 263. Japan Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 264. Japan Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 265. Japan Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 266. Japan Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 267. Japan Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 268. Japan Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. Japan Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 270. Australia Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 271. Australia Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. Australia Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 273. Australia Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 274. Australia Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 275. Australia Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. Australia Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Australia Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 278. South Korea Biologic Medications for Psoriasis Market Size, 2017-2032 (USD Million)
TABLE 279. South Korea Biologic Medications for Psoriasis Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 280. South Korea Biologic Medications for Psoriasis Market Size, by Interleukin 17 Inhibitors, 2017-2032 (USD Million)
TABLE 281. South Korea Biologic Medications for Psoriasis Market Size, by Interleukin 23 Inhibitors, 2017-2032 (USD Million)
TABLE 282. South Korea Biologic Medications for Psoriasis Market Size, by Tumor Necrosis Factor Alpha Inhibitors, 2017-2032 (USD Million)
TABLE 283. South Korea Biologic Medications for Psoriasis Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 284. South Korea Biologic Medications for Psoriasis Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 285. South Korea Biologic Medications for Psoriasis Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 286. Global Biologic Medications for Psoriasis Market Share, by Key Player, 2025
TABLE 287. Global Biologic Medications for Psoriasis Market, Key Experts

Companies Mentioned

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca plc
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol‑Myers Squibb Company
  • Celgene Corporation
  • Celltrion Inc
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Samsung Bioepis Co Ltd
  • UCB S.A.

Related Topics

Related Reports

Psoriasis Therapeutics Market - Global Forecast 2026-2032 - Product Image

Psoriasis Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Middle East Psoriasis Drugs Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Middle East Psoriasis Drugs Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 90 Pages
  • Middle East
From
Psoriasis Drugs Market - Global Forecast 2026-2032 - Product Image

Psoriasis Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Psoriasis Treatment Market - Global Forecast 2026-2032 - Product Image

Psoriasis Treatment Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 177 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.